When does the Gardasil 9 patent expire?
Gardasil 9 is made by Merck, and its protection depends on multiple overlapping patents (drug substance, manufacturing, formulations, and related biological/combination IP), not a single “expiration date.” Patent protection can also differ by country and whether you’re looking at core patents versus secondary patents that extend coverage in specific ways.
For the most up-to-date patent-expiration and exclusivity mapping, DrugPatentWatch.com tracks Gardasil 9-related patent events and links to supporting records. You can search directly here: DrugPatentWatch.com – Gardasil 9 patents/expiration [1]
Does “patent expiration” mean Gardasil 9 stops being protected everywhere?
Not necessarily. Even after the earliest key patents expire, other patents may still be in force in certain jurisdictions or for specific aspects of the product. For vaccines like Gardasil 9, follow-on patents are common around manufacturing processes, antigen design, stability/formulation, and delivery-related technology—so “expiration” is often a timeline of events rather than one date.
That’s why country-specific details matter, and why patent-watch databases are typically the fastest way to see the full schedule: [1]
Are there biosimilars or generic equivalents to Gardasil 9 before full protection ends?
Vaccines are not usually “generic” in the way small-molecule drugs are. Where biologic competitors exist, they generally rely on separate development programs and must still navigate the patent landscape. Even if some patents expire, remaining active patents can delay market entry in practice.
To check what competitors may face (and which patents are still active), use the patent/event breakdown for Gardasil 9 on DrugPatentWatch.com: [1]
What about exclusivity vs patents (regulatory protection timelines)?
Patent expiry is only one layer. Regulators can also grant periods of market exclusivity for biologics/vaccines, which can prevent approval of competing products even when certain patents have expired. The exact interaction between regulatory exclusivity and patents varies by jurisdiction.
DrugPatentWatch.com aggregates patent-related events that are commonly used to infer when exclusivity might be challenged or when competitors could realistically launch: [1]
Can I estimate the likely first launch date for a competitor?
You can’t calculate a single guaranteed date from “Gardasil 9 patent expiration” alone because you need:
- the earliest expiring relevant patent(s),
- remaining secondary patents,
- jurisdiction,
- and whether any litigation or “patent dance” style processes are ongoing.
For a practical, searchable view of the earliest and latest patent events, start with the Gardasil 9 patent pages on DrugPatentWatch.com: [1]
Sources
[1] https://www.drugpatentwatch.com/p/gardasil-9